UCBJF News and Press, Ucb Sa Npv From 04/24/24

2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

2023-12-29 12:01:36 ET More on Pfizer The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Pfizer: Buy The Panic Pfizer in 2024: What to expect? P...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

2023-12-07 23:57:14 ET Summary MoonLake Therapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for inflammatory diseases. Their lead product candidate, Sonelokimab, has shown best-in-class potential in treating Hidradenitis suppurativa and P...

2023-11-14 14:27:51 ET More on UCB SA FDA approves UCB's Bimzelx for plaque psoriasis Historical earnings data for UCB SA Dividend scorecard for UCB SA Financial information for UCB SA For further details see: UCB launches newly approved psoriasis...

2023-06-05 05:02:09 ET Summary ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners and hospital sites featuring its equipment. The company has entered into pre-clinical work and milest...

2023-03-06 17:07:59 ET Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the treatment of autoimmune diseases, including myasthenia gravis (MG). In batoclimab clinical trials by Immunovant, safety concerns emerged w...

Summary argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste. Getting subcutaneous efgartigimod to market is important as ...